Key Market Indicator:
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Tue, 26.03.2024
ParTec AG
First Berlin Equity Research on 26/03/2024 initiated coverage on ParTec AG
(ISIN: DE000A3E5A34/ Bloomberg: JY0 GR). Analyst Simon Scholes placed a BUY
rating on the stock, with a EUR 220.00 price target.
Abstract:
Partec has designed, patented and brought to market a new type of
supercomputer, which for a given initial financial outlay, perform [ … ]
Tue, 26.03.2024
M1 Kliniken AG
First Berlin Equity Research hat ein Research Update zu M1 Kliniken AG
(ISIN: DE000A0STSQ8) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 13,20 auf EUR 18,00.
Zusammenfassung:
Wir bekräftigen unsere Kaufempfehlung für die M1 Kliniken AG (M1) und
erhöhen unser Ku [ … ]
Mon, 25.03.2024
PSI AG
First Berlin Equity Research has published a research update on PSI SE
(ISIN: DE000A0Z1JH9). Analyst Simon Scholes reiterated his BUY rating and
maintained his EUR 30.00 price target.
Abstract:
PSI has published preliminary key figures for 2023. Sales climbed 8.9% to
€269.9m (2022: €247.9m) while EBIT fell to €5.6m (2022: €2 [ … ]
Wed, 20.03.2024
Media and Games Invest SE
First Berlin Equity Research hat ein Research Update zu Media and Games
Invest SE (ISIN: SE0018538068) veröffentlicht. Analyst Ellis Acklin
bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 3,60.
Zusammenfassung:
MGI meldete für den Monat Februar einen Rekordumsatz, der durch ein
organisches Umsatzwachstum ( [ … ]
Mon, 18.03.2024
Deutsche Rohstoff AG
First Berlin Equity Research has published a research update on Deutsche
Rohstoff AG (ISIN: DE000A0XYG76). Analyst Simon Scholes reiterated his BUY
rating and decreased the price target from EUR 47.00 to EUR 46.00.
Abstract:
2023 sales of €196.5m and EBITDA of €158.2m both came in towards the top
end of guidance. Meanwhile, 2023 produ [ … ]
Mon, 18.03.2024
Grand City Properties S.A.
First Berlin Equity Research hat ein Research Update zu Grand City
Properties S.A. (ISIN: LU0775917882) veröffentlicht. Analyst Ellis Acklin
bestätigt seine BUY-Empfehlung und senkt das Kursziel von EUR 12,60 auf EUR
12,50.
Zusammenfassung:
Das Nettomietwachstum auf vergleichbarer Basis (LFL) von 3,3% führte zu
einer guten operat [ … ]
Mon, 11.03.2024
Media and Games Invest SE
First Berlin Equity Research hat ein Research Update zu Media and Games
Invest SE (ISIN: SE0018538068) veröffentlicht. Analyst Ellis Acklin
bestätigt seine BUY-Empfehlung und erhöht das Kursziel von EUR 3,20 auf EUR
3,60.
Zusammenfassung:
MGI überraschte im vierten Quartal mit einer Umsatzsteigerung, die durch
ein starkes J/ [ … ]
Mon, 04.03.2024
European Lithium Limited
First Berlin Equity Research has published a research update on European
Lithium Limited (ISIN: AU000000EUR7). Analyst Simon Scholes reiterated his
BUY rating and maintained his EUR 0.17 price target.
Abstract:
Pricing for lithium chemicals quadrupled during 2021/22 as worldwide sales
of EVs tripled. Since early 2023 prices have collapsed by ca [ … ]
Tue, 27.02.2024
Valneva
First Berlin Equity Research has published a research update on Valneva SE
(ISIN: FR0004056851). Analyst Simon Scholes reiterated his BUY rating and
decreased the price target from EUR 8.90 to EUR 8.60.
Abstract:
FY/23 product revenues recovered strongly (+26% to €144.6m) in line with
resurgent travel activity. The current cash position is [ … ]
Tue, 27.02.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics (Cardiol) announced that the FDA has granted Orphan
Drug Designation (ODD) in the US for its lead drug candid [ … ]